Loading…
Lawsuits allege false statements and undisclosed risks leading to investor losses.
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is facing multiple class action lawsuits related to the safety and efficacy of its gene therapy ELEVIDYS, intended to treat Duchenne muscular dystrophy. The lawsuits, filed on July 28, 2025, allege that Sarepta made false and misleading statements about ELEVIDYS, failing to disclose significant safety risks and severe side effects. These allegations have led to substantial losses for investors.
The company has reported multiple patient deaths associated with ELEVIDYS, which has caused significant drops in its stock price. Specific drops include a 27.44% decline, a 7.13% decline, a 42.12% decline, an 8.01% decline, and a 36% decline at various points. Sarepta Therapeutics has a free float of 99,244,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.